Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025. According to a new report from Deloitte, the life sciences industry will have a ...

Swoop announced its acquisition of MyHealthTeam, creator of one of the largest opted-in patient social networks in the US. The companies share a vision of making vetted information more available for ...

In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols. Biopharma business development and licensing ...

The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation. Bausch + Lomb announced the launch of the second annual Faces of ...

Both companies have produced AI-powered technology that improves data collection and analysis. As the pharma industry continues to embrace new technologies, it’s becoming increasingly clear that the ...

Mary Kosinski joined the firm as global managing director for the sector, along with other leadership additions. Mary Kosinski is the new global managing director of health and life sciences at ...

Klick Health announced its acquisition of market access strategy and value communications specialist Peregrine Market Access. This move is part of Klick’s ongoing efforts to build out its life ...

Jennifer Hawks Bland, CEO of NewYorkBIO, shares her journey from litigation to biotech leadership, discusses fostering innovation in New York's thriving bioscience ecosystem, and outlines her vision ...

Abrysvo and Arexvy will now be required to come with labeling that includes a warning about a potential increased risk of Guillain-Barré Syndrome. The FDA announced that it has mandated updates to the ...

The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is ...

Fast Track designation was based on results from a Phase II study, which demonstrated that VGT-309 was safe, well-tolerated, and enhanced tumor visualization in lung cancer patients. The FDA has ...

John Hood, CEO, Endeavor BioMedicines discusses a potential timeline on availability of ENV-101 for patients with IPF and further validation of the treatment's safety profile. PE: Given the ...